Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma Not Otherwise Specified
• Ebv-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Mediastinal Large B-cell Lymphoma
• Transformed B-cell Lymphoma Unclassifiable with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Epcoritamab (epcoritamab)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: University of Washington | Conditions: B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Status: RECRUITING